Next Article in Journal
Role of Furfural and 5-Methyl-2-furfural in Glucose-Induced Inhibition of 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) Formation in Chemical Models and Pork Patties
Previous Article in Journal
Emerging Biochemical Conversion for Plastic Waste Management: A Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 30
Issue 6
10.3390/molecules30061257
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy

by
Alicia Arroyo-Nogales
,
Guillermo Plaza-Palomo
,
Javier González-Larre
,
Sandra Jiménez-Falcao
and
Alejandro Baeza
*
Materials and Aerospace Production Department, Superior Technic School of Aeronautics and Space Engineering, Politechnic University of Madrid Department Materiales y Producción Aeroespacial, ETSI Aeronáutica y del Espacio, Universidad Politécnica de Madrid, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Molecules 2025, 30(6), 1257; https://doi.org/10.3390/molecules30061257
Submission received: 30 January 2025 / Revised: 21 February 2025 / Accepted: 4 March 2025 / Published: 11 March 2025
(This article belongs to the Section Nanochemistry)
Browse Figures
Versions Notes

Abstract

The use of nanoparticles as drug carriers in oncology has evolved from their traditional role as chemotherapy carriers to their application in immunotherapy, exploiting not only their passive accumulation in solid tumors but also their ability to interact with immune cells. Silicasomes are highly versatile nanoplatforms composed of a mesoporous silica core whose external surface is coated with a lipid bilayer that allows the co-delivery of therapeutic agents having different chemical natures (small molecules, proteins, enzymes, or oligonucleotides, among others). Herein, cutting-edge advances carried out in the development and application of silicasomes are presented, providing a general description of the performance of these nanotransporters. Additionally, the specific load of chemotherapeutic drugs is explored, followed by a discussion of the immunotherapeutic application of silicasomes and the combination of different therapeutic strategies, including theragnosis, in a single silicasome platform, highlighting the enormous potential of these nanosystems.
Keywords: nanomedicine; nanooncology; silicasomes; protocells; drug delivery; controlled release nanomedicine; nanooncology; silicasomes; protocells; drug delivery; controlled release
Graphical Abstract

Share and Cite

MDPI and ACS Style

Arroyo-Nogales, A.; Plaza-Palomo, G.; González-Larre, J.; Jiménez-Falcao, S.; Baeza, A. Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy. Molecules 2025, 30, 1257. https://doi.org/10.3390/molecules30061257

AMA Style

Arroyo-Nogales A, Plaza-Palomo G, González-Larre J, Jiménez-Falcao S, Baeza A. Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy. Molecules. 2025; 30(6):1257. https://doi.org/10.3390/molecules30061257

Chicago/Turabian Style

Arroyo-Nogales, Alicia, Guillermo Plaza-Palomo, Javier González-Larre, Sandra Jiménez-Falcao, and Alejandro Baeza. 2025. "Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy" Molecules 30, no. 6: 1257. https://doi.org/10.3390/molecules30061257

APA Style

Arroyo-Nogales, A., Plaza-Palomo, G., González-Larre, J., Jiménez-Falcao, S., & Baeza, A. (2025). Silicasomes in Oncology: From Conventional Chemotherapy to Combined Immunotherapy. Molecules, 30(6), 1257. https://doi.org/10.3390/molecules30061257

Article Metrics

Back to TopTop